Paper Details

  1. Home
  2. Paper Details

Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer.

Author: HatlevollR, HøstH, KaasaS, LundE, ThorudE

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared combination chemotherapy to symptom management for 87 patients with inoperable, advanced lung cancer. No significant difference in survival was found between the two groups. However, the study notes that the use of radiation therapy, given for symptom relief, may have influenced the results. Despite this, three patients in the symptom management group achieved long-term survival. This study highlights the difficulty in evaluating the effectiveness of chemotherapy for advanced lung cancer when additional treatments like radiation therapy are used concurrently.
Paper Details　
Original Abstract of the Article :
In a randomized clinical trial, 87 patients with inoperable, extensive non-small cell lung cancer (NSCLC) were randomized to receive either combination chemotherapy (cisplatin at 70 mg/m2 intravenously [i.v.] on day 1 and etoposide at 100 mg/m2 i.v. on day 1 and 200 mg/m2 orally on days 2 and 3) or ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/1097-0142(19910515)67:10<2443::aid-cncr2820671008>3.0.co;2-k

データ提供：米国国立医学図書館（NLM）

Symptomatic Treatment vs. Chemotherapy for Extensive NSCLC: A Desert of Uncertainty

Non-small cell lung cancer (NSCLC) is a serious and often fatal disease. This study investigates the efficacy of combination chemotherapy compared to symptomatic treatment for patients with inoperable, extensive NSCLC. The researchers conducted a randomized clinical trial to compare the survival rates of the two treatment approaches.

The study found no statistically significant difference in survival time between the two groups. However, the interpretation of the results was complicated by the use of semicurative radiation therapy in the symptomatic group. The study also noted the presence of three long-term survivors in the symptomatic treatment group.

Navigating the Desert of Lung Cancer Treatment

This study highlights the challenges of treating advanced NSCLC. It suggests that the choice of treatment approach may depend on individual patient characteristics and goals. It's like navigating a desert landscape; there may not be a single right path, and the journey may require flexibility and adaptation to individual needs.

Understanding Lung Cancer

If you or a loved one is diagnosed with lung cancer, it's crucial to seek professional help from an oncologist. They can assess your specific situation and recommend the most appropriate treatment plan. Remember, lung cancer is a complex disease, and navigating the journey requires a collaborative approach with healthcare professionals and a strong support network.

Dr.Camel's Conclusion

This study underscores the ongoing search for effective treatments for advanced NSCLC. The desert of lung cancer research is constantly evolving, and finding the right path for each patient is a complex and challenging process. Continued research and a collaborative approach between healthcare providers and patients are essential for navigating this challenging journey.

Date :
  1. Date Completed 1991-05-22
  2. Date Revised 2019-06-19
Further Info :

Pubmed ID

1849786

DOI: Digital Object Identifier

10.1002/1097-0142(19910515)67:10<2443::aid-cncr2820671008>3.0.co;2-k

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.